# Michel Attal

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/michel-attal/

## Facts

| Field | Value |
| --- | --- |
| Citations | 48,202 |
| Field | Multiple Myeloma Research and Treatments |
| h-index | 104 |
| i10-index | 315 |
| Last Known Institution | Université Fédérale de Toulouse Midi-Pyrénées |
| OpenAlex ID | https://openalex.org/A5025996929 |
| ORCID iD | https://orcid.org/0000-0002-0136-9665 |
| Works | 658 |

## Researcher papers

- [Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma](https://scholariq.org/papers/lenalidomide-bortezomib-and-dexamethasone-with-transplantation-for-myeloma/)
- [Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study](https://scholariq.org/papers/bortezomib-thalidomide-and-dexamethasone-with-or-without-daratumumab-before-and/)
- [Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma](https://scholariq.org/papers/lenalidomide-and-dexamethasone-in-transplant-ineligible-patients-with-myeloma/)
- [Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma](https://scholariq.org/papers/triplet-therapy-transplantation-and-maintenance-until-progression-in-myeloma/)
- [Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial](https://scholariq.org/papers/pembrolizumab-plus-pomalidomide-and-dexamethasone-for-patients-with-relapsed-or/)
- [A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial](https://scholariq.org/papers/a-simplified-frailty-scale-predicts-outcomes-in-transplant-ineligible-patients/)
- [International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation](https://scholariq.org/papers/international-myeloma-working-group-guidelines-for-the-management-of-multiple/)

## Researcher topics

- [Multiple Myeloma Research and Treatments](https://scholariq.org/topics/multiple-myeloma-research-and-treatments/)
- [Protein Degradation and Inhibitors](https://scholariq.org/topics/protein-degradation-and-inhibitors/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Hematopoietic Stem Cell Transplantation](https://scholariq.org/topics/hematopoietic-stem-cell-transplantation/)
- [Acute Myeloid Leukemia Research](https://scholariq.org/topics/acute-myeloid-leukemia-research/)

## Researcher university

- [Université Fédérale de Toulouse Midi-Pyrénées](https://scholariq.org/institutions/universite-federale-de-toulouse-midi-pyrenees/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.